A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 32
- Population
- ALL · 55 Years to 80 Years
- Duration
- 2019-02-12 to 2020-09-01
- Intervention
- Placebo (twice daily); Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)
- Comparator
- Placebo
- Outcomes measured
- Presence of Satellite Cells — Change from baseline up to 45 days; Activation of Satellite cells — Change from baseline up to 45 days; Presence of macrophages — Change from baseline up to 45 days; Presence of Fibro/Adipogenic Progenitors — Change from baseline up to 45 days; Presence of damaged muscle fibers — Change from baseline up to 45 days; Presence of muscle regenerative fibers — Change from baseline up to 45 days; Presence of autophagy in relation to muscle damage — Change from baseline up to 45 days; Lipid accumulation in skeletal muscle tissue and liver — Change from baseline to 8 days; Blood glucose response in relation to muscle damage — Change from baseline to 8 days; Body composition (lean body mass and fat body mass) — Change from baseline to 45 days; Muscle strength — Change from baseline up to 45 days
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- NAD metabolism · 100%Title contains controlled term: nicotinamide riboside. Abstract contains controlled term: nad+, nicotinamide riboside. Source terminology contains: nicotinamide riboside. Title supplies longevity context: elderly. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.